Last reviewed · How we verify
Fosmidomycin and Clindamycin co-administration
Fosmidomycin inhibits the enzyme 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), which is involved in the biosynthesis of isoprenoids, while clindamycin inhibits protein synthesis by binding to the 50S ribosomal subunit.
Fosmidomycin inhibits the enzyme 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), which is involved in the biosynthesis of isoprenoids, while clindamycin inhibits protein synthesis by binding to the 50S ribosomal subunit. Used for Treatment of malaria caused by Plasmodium falciparum, Treatment of bacterial infections, including those caused by Streptococcus and Staphylococcus species.
At a glance
| Generic name | Fosmidomycin and Clindamycin co-administration |
|---|---|
| Sponsor | Jomaa Pharma GmbH |
| Drug class | Antibiotic |
| Target | DXR, 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
Fosmidomycin targets the DXR enzyme, which is crucial for the production of isoprenoids, a class of molecules involved in various cellular processes. By inhibiting DXR, fosmidomycin disrupts the isoprenoid biosynthesis pathway. Clindamycin, on the other hand, works by binding to the 50S ribosomal subunit, which prevents the elongation of the polypeptide chain during protein synthesis.
Approved indications
- Treatment of malaria caused by Plasmodium falciparum
- Treatment of bacterial infections, including those caused by Streptococcus and Staphylococcus species
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
Key clinical trials
- Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated P.Falciparum Malaria in Children (PHASE2)
- Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: